Principal Securities’s Anixa Biosciences ANIX Stock Holding History

Principal Securities’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$3.3K	–	1445
2025 Q3	$3.3K	Hold	1,000	–	–	﹤0.01%	3092
2025 Q2	$3.3K	Hold	1,000	–	–	﹤0.01%	2992
2025 Q1	$2.32K	Hold	1,000	–	–	﹤0.01%	3007
2024 Q4	$2.32K	Hold	1,000	–	–	﹤0.01%	3001
2024 Q3	$3.15K	Hold	1,000	–	–	﹤0.01%	2819
2024 Q2	$2.21K	Hold	1,000	–	–	﹤0.01%	2889
2024 Q1	$3.12K	Hold	1,000	–	–	﹤0.01%	2753
2023 Q4	$3.88K	Buy	+1,000	New	+$3.37K	﹤0.01%	2623

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Principal Securities's ANIX Position: Q4 2025 in Review

Principal Securities sold out of Anixa Biosciences (ANIX) in Q4 2025, closing a stake of 1,000 shares — an estimated $3.3K sold.

Principal Securities first reported a position in ANIX in Q4 2023 and held it in 8 quarters. The position peaked at $3.88K in Q4 2023. 71 funds tracked by Wall St. Rank hold ANIX as of Q4 2025.

Principal Securities reported no remaining Anixa Biosciences position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 1,000 Anixa Biosciences shares in Q4 2025, an estimated $3.3K.
Principal Securities first reported a position in Anixa Biosciences in Q4 2023 and held it in 8 quarters.
Principal Securities's Anixa Biosciences position peaked at $3.88K in Q4 2023.
71 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.